University of Surrey

Test tubes in the lab Research in the ATI Dance Research

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

Lee, SM, Khan, I, Upadhyay, S, Lewanski, C, Falk, S, Skailes, G, Marshall, E, Woll, PJ, Hatton, M, Lal, R , Jones, R, Toy, E, Chao, D, Middleton, G, Bulley, S, Ngai, Y, Rudd, R, Hackshaw, A and Boshoff, C (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial LANCET ONCOLOGY, 13 (11). pp. 1161-1170.

Full text not available from this repository.
Item Type: Article
Authors :
NameEmailORCID
Lee, SMUNSPECIFIEDUNSPECIFIED
Khan, Ii.khan@surrey.ac.ukUNSPECIFIED
Upadhyay, SUNSPECIFIEDUNSPECIFIED
Lewanski, CUNSPECIFIEDUNSPECIFIED
Falk, SUNSPECIFIEDUNSPECIFIED
Skailes, GUNSPECIFIEDUNSPECIFIED
Marshall, EUNSPECIFIEDUNSPECIFIED
Woll, PJUNSPECIFIEDUNSPECIFIED
Hatton, MUNSPECIFIEDUNSPECIFIED
Lal, RUNSPECIFIEDUNSPECIFIED
Jones, RUNSPECIFIEDUNSPECIFIED
Toy, EUNSPECIFIEDUNSPECIFIED
Chao, DUNSPECIFIEDUNSPECIFIED
Middleton, GUNSPECIFIEDUNSPECIFIED
Bulley, SUNSPECIFIEDUNSPECIFIED
Ngai, YUNSPECIFIEDUNSPECIFIED
Rudd, RUNSPECIFIEDUNSPECIFIED
Hackshaw, AUNSPECIFIEDUNSPECIFIED
Boshoff, CUNSPECIFIEDUNSPECIFIED
Date : 1 November 2012
Identification Number : 10.1016/S1470-2045(12)70412-6
Uncontrolled Keywords : Science & Technology, Life Sciences & Biomedicine, Oncology, ONCOLOGY, GROWTH-FACTOR RECEPTOR, METASTATIC COLORECTAL-CANCER, PERFORMANCE STATUS, STANDARD CHEMOTHERAPY, OPEN-LABEL, RASH, MULTICENTER, COMBINATION, GEFITINIB, CETUXIMAB
Related URLs :
Depositing User : Symplectic Elements
Date Deposited : 17 May 2017 10:40
Last Modified : 17 May 2017 10:40
URI: http://epubs.surrey.ac.uk/id/eprint/828759

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800